Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Purity >98.0% (GC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates Ka Bohloeki bo Phahameng
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Lebitso la Lik'hemik'hale | Methyl 4-Amino-2-Methoxybenzoate |
Litlhaloso tse tšoanang | 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester |
Nomoro ea CAS | 27492-84-8 |
Nomoro ea KAtse | RF-PI1974 |
Boemo ba Setoko | Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane |
Foromo ea limolek'hule | C9H11NO3 |
Boima ba Molek'hule | 181.19 |
Botenya | 1.179±0.060 g/cm3 |
Brand | Ruifu Chemical |
Ntho | Litlhaloso |
Ponahalo | Phofo e tšoeu ho isa ho e tšoeu kapa likristale |
Mokhoa oa Bohloeki / Analysis | >98.0% (GC) |
Mokhoa oa Bohloeki / Analysis | 97.5~102.5 (Nonaqueous Titration) |
Melting Point | 157.0~161.0℃ |
Tahlehelo ka ho Omisa | <1.00% |
Litšila ka Kakaretso | <2.0% |
Infrared Spectrum | E Ikamahanya le Sebopeho |
Proton NMR Spectrum | E Ikamahanya le Sebopeho |
Tekanyetso ea Teko | Maemo a Khoebo |
Tšebeliso | Bohareng ba Lenvatinib Mesylate (CAS: 857890-39-2) |
Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo
Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) e ka sebelisoa e le bohareng ba Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib ke lithethefatsi tsa kankere ea qoqotho tse entsoeng ke Eisai Corporation ea Japane (Code: E7080), e leng ea inhibitor ea oral multi-receptor tyrosine kinase (RTK) 'me e ka thibela mosebetsi oa kinase oa vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), le VEGFR3 (FLT4).Lenvatinib e ka boela ea thibela ho kenya letsoho ha li-RTK tse ling ho pathological angiogenesis, ho hōla ha hlahala, le tsoelo-pele ea kankere ntle le mesebetsi ea bona e tloaelehileng ea lisele tse kenyeletsang fibroblast growth factor (FGF) receptors FGFR1, 2, 3, le 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, le RET.[Lipontšo]: Lenvatinib e loketse ho phekola bakuli ba mofetše oa qoqotho oa ho ipheta-pheta kapa mofuta oa metastasis, mofuta oa tsoelo-pele le mofuta o fapaneng oa iodine-refractory.Ka la 13 Hlakola, 2015, US FDA e amohetse sethethefatsi sa anticancer Lenvatinib bakeng sa kalafo ea mofets'e oa qoqotho.Lenvatinib ke inhibitor ea enzyme e nang le lipheo tse ngata, e khonang ho thibela VEGFR2 le VEGFR3 (vascular endothelial growth factor receptor).Lebitso la khoebo la Lenvatinib ke Lenvima.Ka May 20, 2015, European Medicines Agency (EMA) e amohetse Lenvatinib bakeng sa phekolo ea kankere ea qoqotho e hlaselang, e tsoetseng pele kapa ea metastatic (papillary, follicular, Hurthle type) kankere ea qoqotho (DTC).Tekong, nako ea ho phela ha bakuli ba DTC ea radioactive iodine-refractory DTC ba phekoloang ka Lenvatinib e ne e le likhoeli tse 18 ha boleng ba bakuli ba nkang placebo e le likhoeli tse 3 feela.